<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370172</url>
  </required_header>
  <id_info>
    <org_study_id>201501</org_study_id>
    <secondary_id>2015-005576-22</secondary_id>
    <nct_id>NCT03370172</nct_id>
  </id_info>
  <brief_title>Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A Subjects</brief_title>
  <official_title>A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxalta Innovations GmbH, now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and determine the dose of BAX 888
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of BAX 888-related adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 3 years per participant.</time_frame>
    <description>Includes serious or non-serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median plasma Factor VIII (FVIII) activity level</measure>
    <time_frame>From screening visit to last study visit, at approximately 40 visits (screening &amp; study visits), up to approximately 3 years per participant</time_frame>
    <description>Circulating plasma FVIII activity level, based on one-stage clotting assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median plasma Factor VIII (FVIII) antigen level</measure>
    <time_frame>From screening visit to last study visit, at approximately 40 visits (screening &amp; study visits), up to approximately 3 years per participant</time_frame>
    <description>Circulating plasma FVIII antigen (protein) level in the plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleed rate (ABR)</measure>
    <time_frame>Throughout the study period of approximately 3 years per participant.</time_frame>
    <description>Annualized bleed rate (ABR) in comparison to before gene transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of exogenous Factor VIII (FVIII)</measure>
    <time_frame>Historical data from 12 months prior to study enrollment; and 12 months post-infusion and 3 years post-infusion.</time_frame>
    <description>The percentage of participants with a reduction in exogenous FVIII consumption 12 months post-infusion and 3 years post-infusion compared to the historical consumption (consumption of exogenous FVIII during the 12 month period prior to BAX 888 infusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with inhibitory antibodies to FVIII</measure>
    <time_frame>Throughout the study period of approximately 3 years per participant.</time_frame>
    <description>Development of inhibitory antibodies to FVIII (Nijmegen assay).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with total binding antibodies to FVIII</measure>
    <time_frame>Throughout the study period of approximately 3 years per participant.</time_frame>
    <description>Development of total binding antibodies to FVIII (IgG and IgM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with humoral and cell-mediated immune response to AAV8 and FVIII proteins.</measure>
    <time_frame>Throughout the study period of approximately 3 years per participant.</time_frame>
    <description>Humoral (antibody-mediated) and cell-mediated immune response to adeno-associated virus (AAV8) (the vector) and Factor VIII (FVIII) proteins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surveillance of AAV8 genome shedding</measure>
    <time_frame>Throughout the study period of approximately 3 years per participant.</time_frame>
    <description>Surveillance of adeno-associated virus (AAV8) genome shedding in blood, saliva, semen, urine and stool</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAX 888</intervention_name>
    <description>An Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>BAX888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, aged 18 to 75 years at the time of screening.

          2. Established severe hemophilia A (factor VIII procoagulant activity (FVIII:C) &lt;1%,
             measured following ≥5 days without factor VIII (FVIII) treatment), and/or documented
             intron 1 inversion or intron 22 inversion mutation in the F8 gene, consistent with
             severe hemophilia A, AND documented evidence of ≥3 hemorrhages over the previous 12
             months requiring treatment with exogenous FVIII or use of FVIII prophylaxis because of
             history of frequent bleeding episodes.

          3. History of &gt;150 exposure days to exogenously administered FVIII concentrates or
             cryoprecipitate.

          4. Normal prothrombin time (PT).

          5. Sexually active men must agree to use barrier contraception (combination of a condom
             and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized,
             or contraception-practicing partners for a minimum of 6 months after administration of
             BAX 888, or until BAX 888 genomes are no longer detected in the semen, whichever is
             sooner.

          6. Participant is willing and able to comply with the requirements of the protocol,
             including provision of semen samples, maintenance of a diary of bleeding episodes and
             FVIII protein use.

          7. Signed informed consent.

        Exclusion Criteria:

          1. Bleeding disorder(s) other than hemophilia A.

          2. Personal laboratory evidence of having developed inhibitors to FVIII protein at any
             time (≥0.6 Bethesda units (BU) on any single test).

          3. Documented prior allergic reaction to any FVIII product.

          4. Adeno-associated virus, serotype 8 (AAV8) neutralizing antibody titer greater than or
             equal to 1:5.

          5. Positive AAV8-specific T-cell ELISPOTs for any AAV8 peptide pools.

          6. Known hypersensitivity to prednisolone or prednisone, or to any of the excipients.

          7. Having a disease in which treatment with prednisolone or prednisone is not tolerated
             (including but not limited to osteoporosis with vertebral fractures, severe labile
             hypertension, and brittle diabetes).

          8. Evidence of markers of potential underlying risk for autoimmune mediated hepatic
             disease:

               1. Anti-smooth muscle antibody assay results ≥40 (Inova QUANTA LiteTM Actin IgG
                  enzyme-linked immunosorbent assay [ELISA]); values of 31 to 39 will be flagged as
                  possibly abnormal and the Investigator and Medical Monitor will evaluate the
                  participant for eligibility.

               2. Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers.

               3. Total immunoglobulin G (IgG) &gt;1.5x upper limit of normal (ULN).

               4. Antinuclear antibody (ANA) titer &gt; 1:320; OR ANA titer &gt; 1:80 if demonstrated
                  concurrently with alanine aminotransferase (ALT) that is &gt; ULN.

          9. Active Hepatitis C: As indicated by detectable hepatitis C virus (HCV) ribonucleic
             acid (RNA) by polymerase chain reaction (PCR).

         10. Hepatitis B: If surface antigen is positive.

         11. Seropositive for Human Immunodeficiency Virus (HIV).

         12. Receiving systemic antiviral and/or interferon therapy within 4 weeks prior to
             enrollment.

         13. Clinically significant infections (e.g., systemic fungal infections) requiring
             systemic treatment.

         14. Known immune disorder (including myeloma and lymphoma).

         15. Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or
             other disorders.

         16. An absolute neutrophil count &lt;1000 cells/mm^3.

         17. Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the
             following:

               1. Platelet count of &lt;150,000/μL.

               2. Albumin ≤3.5 g/dL.

               3. Total bilirubin &gt;1.5x ULN and direct bilirubin ≥0.5 mg/dL.

               4. ALT or aspartate aminotransferase (AST) &gt;1.0x ULN.

               5. Alkaline phosphatase (AP) &gt;2.0x ULN.

               6. History of liver biopsy indicating moderate or severe fibrosis (Metavir staging
                  of F2 or greater).

               7. History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy.

               8. FibroSURE Score of ≥0.4.

         18. Serum creatinine &gt;1.5 mg/dL.

         19. Urine protein &gt;30 mg/dL OR &gt;0.5 g/day.

         20. Body mass index &gt;38.

         21. Major surgery or an orthopedic surgical procedure planned within 6 months after
             enrollment.

         22. Acute or chronic disease that, in the opinion of the investigator, would adversely
             affect subject safety or compliance or interpretation of study results.

         23. Received an AAV vector previously or any other gene transfer agent in the previous 12
             months prior to Study Day 0.

         24. Received an investigational intervention or participated in another clinical trial
             within 4 weeks prior to enrollment or within 5 half-lives of the investigational drug
             administration, whichever is longer.

         25. Significant cardiovascular disease (such as New York Heart Association Class III or IV
             cardiac disease, congestive heart failure, myocardial infarction within the previous 6
             months, unstable arrhythmias, or unstable angina) or significant pulmonary disease
             (including obstructive pulmonary disease).

         26. Recent history of psychiatric illness or cognitive dysfunction (including drug or
             alcohol abuse) that in the opinion of the investigator, is likely to impair subject's
             ability to comply with protocol mandated procedures.

         27. Sensitivity to penicillin.

         28. Participant is a family member or employee of the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Chapin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rocio Iturbe, MSc</last_name>
    <phone>+1-617-588-8275</phone>
    <email>rocio.iturbe@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orthopaedic Hemophilia Treatment Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gulf States Hemophilia and Thrombophilia Center City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

